Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
about
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.Effect of MDR1 gene polymorphisms on mortality in paraquat intoxicated patients.A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.MDR1 gene polymorphisms are associated with glucocorticoid-induced avascular necrosis of the femoral head in a Chinese population.The missing linkage: what pharmacogenetic associations are left to find in CYP3A?Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients.Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients.Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus.Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers.Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
P2860
Q30375556-2521D9B7-961A-48EA-ABD7-C1A07AD7EDCEQ37193122-EF1DAFBC-1235-47C3-B546-F53B93CD0495Q37207789-1BE00E3B-B904-4958-90F3-EDEE79501353Q37478703-70295443-467B-49CB-A91A-943C722C998AQ37628529-A577D63A-544B-4CD4-9489-A9E76C38C5CCQ37646778-275D695A-AEA5-4A99-B066-96F6C9A5F849Q38247190-F03E67EE-CB72-479D-8BA9-940C0441D2E6Q38414396-DCBF2BD1-12A7-4076-B005-B62DB2077670Q39452105-47C08118-5FB2-46B8-9410-5086DACA5B40Q39816513-CA45F02B-B9C8-4A0C-8020-F219CAB90461Q42388674-CDEB1E29-CEF2-49D7-A9F4-A9D00A5F53D2Q43150808-FC127FB1-FF8E-4A36-805D-262F286AB1F3Q44074090-0E2EEB7D-89EE-4E1A-AA35-BABF93828C5EQ46173047-004A4D82-FDE3-4ED6-B78D-325B6161A244Q51365892-AA04AB86-ACD8-4F67-BE08-61EAE2BC9DEAQ54520157-E79DAC04-B610-4E90-AB6A-A128BDC1AE21
P2860
Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Influence of the CYP3A5 and MD ...... us in healthy Korean subjects.
@ast
Influence of the CYP3A5 and MD ...... us in healthy Korean subjects.
@en
type
label
Influence of the CYP3A5 and MD ...... us in healthy Korean subjects.
@ast
Influence of the CYP3A5 and MD ...... us in healthy Korean subjects.
@en
prefLabel
Influence of the CYP3A5 and MD ...... us in healthy Korean subjects.
@ast
Influence of the CYP3A5 and MD ...... us in healthy Korean subjects.
@en
P2093
P2860
P1476
Influence of the CYP3A5 and MD ...... us in healthy Korean subjects.
@en
P2093
Jong-Eun Lee
Kyung H Kim
Kyungsoo Park
Seong B Jang
Yoon J Lee
P2860
P304
P356
10.1111/J.1365-2125.2007.02874.X
P407
P577
2007-03-28T00:00:00Z